Investor Presentaiton

R&D investor presentation The semaglutide obesity phase 3a STEP programme has completed Phase 3 STEP programme STEP 1 Semaglutide 2.4 mg Placebo Semaglutide 1 mg 2019 Weight management n=1,961 Duration: 68 weeks 2020 STEP 2 Semaglutide 2.4 mg Placebo STEP 3 Weight management with T2D n=1,210 Duration: 68 weeks Semaglutide 2.4 mg + IBT Weight management with IBT n=611 Duration: 68 weeks Placebo + IBT Sema 2.4 mg Placebo STEP 4 Sema 2.4 mg Sema: Semaglutide; IBT: Intensive behaviour therapy Sustained weight management n=902 Duration: 68 weeks 2021 Prep for filing Regulatory review and decision 31

View entire presentation